The Cooper Companies, Inc. (COO): BCG Matrix [June-2026 Updated]

This ready-made analysis gives you a clear, research-based view of The Cooper Companies, Inc. across Stars, Cash Cows, Question Marks, and Dogs, so you can quickly see where growth, market share, and capital should matter most. You'll learn why CooperVision's $723.5M Q2 2026 revenue, roughly one-third global contact lens share, MyDay and MiSight growth, Biofinity's steady cash generation, CooperSurgical's $358.0M Q2 revenue, and the $271.6M litigation charge all shape portfolio balance, risk, and capital allocation through fiscal 2026.

The Cooper Companies, Inc. - BCG Matrix Analysis: Stars

The Cooper Companies, Inc.'s Star businesses are centered on CooperVision's premium contact lens portfolio, especially MyDay and MiSight. These products combine strong growth with large market presence, which is the core BCG Star profile.

Stars are business units with high market growth and high relative market share. They usually need continued investment to defend position, but they also have the scale to become major cash generators later. In The Cooper Companies, Inc.'s case, CooperVision fits this pattern because it held roughly one-third of global contact lens wearers in an $11B market while still posting above-market growth.

CooperVision generated $723.5M of revenue in Q2 2026, up 8.0% reported and 4.0% organically. That matters because organic growth shows the business is expanding without relying only on acquisitions or foreign exchange. For a mature medical device company, that rate is strong and supports Star classification.

MYDAY AND MISIGHT LEAD the Star case because they sit in the fastest-growing part of the portfolio. MyDay delivered double-digit revenue growth in Q2 2026, while MiSight grew 23.0% in Q1 2026 after Japan launches. That tells you the company is not just defending share; it is still expanding into premium categories and new regions.

MyDay matters because it sits in the premium daily disposable silicone hydrogel category, which is where consumer and practitioner demand is moving. Silicone hydrogel lenses let more oxygen reach the eye than standard hydrogel lenses, so they are often positioned as a higher-performance option. MyDay multifocal and toric launches extend that platform into adjacent prescriptions, which widens the addressable market and supports recurring revenue.

MiSight is important for a different reason. It targets pediatric myopia management, a category with a clear long-term growth driver as more children need vision correction earlier in life. The company's Q1 2026 23.0% growth after Japan launches shows the category can scale internationally. In BCG terms, that combination of high growth and strategic relevance supports Star treatment even if the current revenue base is smaller than the core lens franchise.

PREMIUM DAILY DISPOSABLE SHIFT is the main strategic engine behind this Star classification. CooperVision's business is centered on premium daily disposable silicone hydrogel contact lenses, and that is the clearest high-growth, high-share investment zone in the portfolio. The company's premium upgrade strategy is tied to Aquaform technology, which supports comfort and oxygen permeability, two buying factors that matter in contact lenses.

CooperVision remained the largest revenue contributor at 67.0% of company sales in June 2026. That scale matters because large share gives the company better leverage over manufacturing, distribution, and retailer relationships. It also gives management room to keep investing in product launches while still maintaining profitability.

• MyDay supports premium daily disposable growth.
• MyDay multifocal and toric broaden the prescription base.
• MiSight adds a high-growth pediatric myopia category.
• Aquaform technology strengthens product differentiation.
• CooperVision's 67.0% revenue contribution shows scale behind the strategy.

MYOPIA MANAGEMENT EXPANDS the Star profile because it adds a long-duration growth theme. Myopia correction in children is becoming a bigger industry focus, and that expands the addressable market for MiSight. The company's Q1 2026 growth of 23.0% after Japanese launches shows that execution is matching the opportunity.

The broader contact lens market was about $11B in June 2026, which gives CooperVision a large commercial base to work from. A large market matters in BCG analysis because a high-share business can keep growing without immediately hitting saturation. CooperVision's Q2 2026 revenue of $723.5M also shows that it can scale while still investing in specialty segments like myopia management.

GEOGRAPHIC SHARE ADVANCE reinforces the Star view because the company is still growing across major regions. In Q2 2026, Americas revenue grew 7.0% and EMEA revenue grew 6.0%. Those are healthy results for a business already operating at scale.

Asia Pacific revenue fell 6.0% to $130.6M, so the story is not uniform across all regions. Even so, CooperVision still held roughly one-third of global contact lens wearers, which is a strong competitive position. J&J Vision Care held 35.0% to 40.0% market share and Alcon held 14.2%, so CooperVision remains one of the few global scale leaders.

The company's FY 2026 organic revenue guidance of 3.5% to 4.5% still looks respectable for a business of this size. That range shows management expects continued expansion even from a large installed base. In BCG terms, that is exactly what a Star should do: grow faster than the market while protecting a strong share position.

GROWTH FUNDED BY SCALE is what keeps the Star quadrant sustainable. CooperVision's leadership position gives it the cash and channel reach needed to support premium product development, distribution, and sales execution. That is important because Stars usually consume capital before they turn into Cash Cows.

Company-wide free cash flow in Q2 2026 was $96.4M. Free cash flow means cash left after operating costs and capital spending, and it matters because it shows whether the business can fund growth internally. Cooper ended the quarter with $2.3B in net debt and $20.9M of interest expense, so disciplined cash generation still matters.

The remaining share repurchase authorization of $860.8M shows management still has flexibility to return capital while supporting growth investments. The business also benefits from $50M of annual savings from the Q4 2025 restructuring starting in fiscal 2026. Those savings improve the funding base for premium innovation and channel expansion.

• $96.4M of Q2 2026 free cash flow supports internal funding.
• $2.3B of net debt means capital allocation must stay disciplined.
• $20.9M of interest expense reduces financial flexibility but remains manageable in context.
• $860.8M of repurchase authorization signals spare capital capacity.
• $50M of annual restructuring savings improves operating leverage.

For academic work, the Star classification is strongest when you connect market share, growth rate, and strategic investment. In this case, CooperVision's premium daily disposable franchise, myopia management growth, and one-third global wearer share all support the same argument: the business is growing in a large market and still has room to expand.

The Cooper Companies, Inc. - BCG Matrix Analysis: Cash Cows

The Cooper Companies, Inc. has a strong Cash Cow profile in its mature vision care and surgical franchises. These businesses combine large market share, steady growth, high margins, and consistent free cash flow, which lets them fund investment, debt service, and capital returns.

Biofinity is the clearest Cash Cow inside CooperVision because it sits at the center of a mature lens base with scale, recurring demand, and strong operating leverage. In Q2 2026, CooperVision generated $723.5M of revenue and represented 67.0% of total company sales, showing how much of the company still depends on a core cash-generating portfolio.

The mature lens base is the main reason this business qualifies as a Cash Cow. CooperVision holds roughly one-third of global contact lens wearers, which gives it the market share needed to produce cash without relying on aggressive reinvestment. In BCG terms, that is the ideal Cash Cow setup: high relative market share in a slow-to-moderate growth market.

The company's Q2 2026 non-GAAP operating margin reached 27.5%, up 260 basis points year over year. A margin increase like this matters because it shows that each dollar of sales is producing more operating profit, which strengthens the cash available after expenses. Free cash flow of $96.4M in the quarter, despite $86.4M of capital expenditures, confirms that the business is generating cash after funding maintenance and growth investment.

• Americas growth of 7.0% and EMEA growth of 6.0% show a mature but still reliable demand base.
• The contact lens market is about $11B, giving the company scale in a large established category.
• High market share reduces the need for heavy discounting and supports stable pricing power.
• Stable cash generation matters because it can fund R&D, acquisitions, debt reduction, and share repurchases.

Office and Surgical Products also fits the Cash Cow logic, even though it is smaller than vision care. The business generated $214.0M of Q2 2026 revenue and grew 4.0% organically, which is steady rather than fast. That kind of growth is useful in a mature portfolio because it adds dependable cash without requiring the kind of heavy spending usually needed in high-growth markets.

The broader CooperSurgical segment posted $358.0M of revenue in Q2 2026, but the Office and Surgical Products piece is the more stable cash engine inside it. Women's health and procedural products tend to have recurring demand and lower volatility than early-stage categories, so they fit the Cash Cow profile better than a question mark or star in the BCG Matrix.

Cost discipline strengthens the cash story. The Q4 2025 restructuring was completed to deliver $50M in annual savings starting in fiscal 2026. Lower fixed costs improve conversion from revenue to earnings and cash, which is why the company could report $1.21 in non-GAAP earnings per share in Q2 2026 while still maintaining a strong margin base.

The company also returned cash to shareholders. It repurchased $13.1M of stock in Q2 2026 at an average price of $75.84, and remaining repurchase authority of $860.8M shows it still has room to buy back shares if cash generation stays strong. Buybacks are a common use of Cash Cow cash because mature businesses often produce more cash than they need for internal reinvestment.

The business mix also supports the Cash Cow label. Vision care represented 67.0% of sales, while surgical and fertility contributed the remaining 33.0%. That split matters because the larger, more mature vision care base is the main source of dependable cash, while the smaller surgical platform adds diversification and additional cash flow.

Tax and leverage are manageable for a mature cash business. The effective tax rate was 15.4% in Q2 2026, close to the 15.5% fiscal 2026 guidance, which supports predictability in net income and cash planning. Net debt of $2.3B is meaningful, but it is manageable relative to the company's scale and recurring cash generation, especially when free cash flow stays positive.

• Stable revenue reduces earnings volatility.
• High margins improve cash conversion from sales.
• Moderate capex protects free cash flow.
• Share buybacks show excess cash after operations.
• Guided tax rates improve forecasting reliability.

For academic work, this makes a clear Cash Cow case study. The company's mature market position, strong operating margin, steady free cash flow, and shareholder returns show how a leadership franchise in a low-to-moderate growth market can keep generating cash long after the fastest growth phase has passed.

The Cooper Companies, Inc. - BCG Matrix Analysis: Question Marks

The Cooper Companies, Inc. has several businesses that fit the Question Mark quadrant because they operate in attractive growth areas but do not show clear, dominant share positions in the data provided. That means these units need more capital, sharper execution, and closer portfolio review before they can be treated as Stars.

Question Marks are the parts of the portfolio where growth is real, but leadership is not yet secure. For The Cooper Companies, Inc., that matters because capital can either build scale in the right businesses or get tied up in units that never earn enough share to justify the spend.

CooperSurgical Fertility is a classic Question Mark. Fertility revenue reached $144.0M in Q2 2026 and grew 10.0% organically, which shows healthy demand. But the available data do not show that The Cooper Companies, Inc. has a clear market-share lead, so the business looks promising without being proven. The June 2024 acquisition of a fertility business focused on sperm separation devices for $33.5M shows management is still investing to widen the product set. Higher R&D expense, including project spend and pharmacovigilance fees, also tells you the company is still funding development rather than harvesting mature returns.

That matters strategically because Question Marks absorb capital fast. If the fertility platform gains scale, it can move toward Star status. If not, it risks becoming a weak return on invested capital, which is the amount of profit generated for each dollar of capital used.

CooperSurgical as a whole also carries Question Mark traits because of strategic uncertainty. The Board announced a formal strategic review in December 2025 to simplify operations and improve long-term shareholder value. By June 2026, management said it had received significant indications of interest for the CooperSurgical business. At the same time, CSI still generated $358.0M in Q2 revenue and made up 33.0% of company sales. That means the segment is economically important, but its future ownership structure is not settled.

FY 2026 CSI revenue guidance of $1.40B to $1.41B confirms the segment is too large to ignore. In BCG terms, that is exactly where a Question Mark creates tension: high relevance, uncertain end state, and a need to decide whether to invest, restructure, or sell.

• High revenue base supports continued strategic attention.
• Unclear end state limits long-term planning visibility.
• Potential buyer interest creates optionality for capital allocation.
• Without clear ownership clarity, execution risk stays elevated.

MiSight and the myopia expansion bet also fit Question Mark territory. MiSight posted 23.0% growth in Q1 2026 after Japan launches, which signals strong demand in pediatric myopia management. The broader contact lens market is about $11B, and myopia treatment demand is rising globally, so the addressable market is attractive. CooperVision is also expanding MyDay multifocal and toric lenses, which broadens the platform.

Still, growth alone does not make this a Star. The company did not disclose a clear category-leading share in pediatric myopia management, and Asia Pacific softness in Japan and China shows the market is uneven. For academic analysis, that is important because Question Marks are usually defined by the gap between market opportunity and actual share capture.

New acquisitions strengthen the Question Mark case. The $50M final installment for Cook Medical assets due November 1, 2025, plus the $33.5M fertility acquisition, show that CooperSurgical is still assembling capabilities. Q2 2026 CooperSurgical fertility revenue of $144.0M and office and surgical revenue of $214.0M point to a mixed portfolio rather than a fully settled market leader across each category.

The segment also faced a $271.6M litigation charge in Q2 2026. That weakens near-term earnings quality, which is the degree to which profits are repeatable and backed by core operations. So even where growth is solid, legal costs and integration spending can reduce the cash available for expansion.

Capital allocation optionality is one of the clearest Question Mark signals in this business. The company had $860.8M of remaining repurchase authorization and a June 2026 market capitalization of $12.14B at a $62.02 share price. At the same time, CooperSurgical is under strategic review and has attracted indications of interest. FY 2026 company revenue guidance of $4.285B to $4.321B and non-GAAP EPS guidance of $4.58 to $4.66 show the overall group is still expanding.

That creates a capital choice problem. Management can keep funding the platform, separate it, or sell it. In BCG terms, that flexibility is what makes a Question Mark: the business may become a Star if execution is strong, but it also may need to be exited if returns do not justify the investment.

• Buybacks signal that management still has capital return capacity.
• Strategic review suggests the portfolio may be reshaped.
• Revenue growth supports reinvestment, but not automatic expansion.
• Legal and integration costs raise the hurdle for future capital deployment.

The right academic takeaway is that these units should not be judged only on revenue growth. They must be measured against market share, capital intensity, execution risk, and strategic fit. In The Cooper Companies, Inc., the Question Mark businesses are attractive enough to fund, but not yet strong enough to treat as settled winners.

The Cooper Companies, Inc. - BCG Matrix Analysis: Dogs

The weakest parts of The Cooper Companies, Inc. fit the Dogs category because they show low growth, weak momentum, and heavy operational or legal drag. The clearest examples are the legacy hydrogel contact lens base in Asia Pacific and the embryo culture media franchise inside CooperSurgical.

In BCG Matrix terms, a Dog is a business with low relative market share in a low-growth market. That matters because these units usually tie up capital, management attention, and cash without producing strong returns. For The Cooper Companies, Inc., the issue is not the entire company, but specific product lines and legacy exposures that are being de-emphasized or burdened by disputes and cost pressure.

APAC legacy hydrogel is the clearest Dog. The company said Asia Pacific contact lens revenue fell 6.0% to $130.6M in Q2 2026, and management explicitly said it is continuing portfolio rationalization for legacy hydrogel contact lenses in the region. That is the opposite of a growth story. When a company is actively shrinking or simplifying a product set, it usually means the line no longer deserves much reinvestment. In BCG terms, that is classic Dog behavior: low growth, weak competitive position, and limited strategic relevance.

Japan and China softness deepen the same conclusion. Management said market weakness in those countries is hurting the vision business, even though CooperVision still grew 8.0% reported overall. That gap matters. It shows the growth engine is coming from premium franchises, while the older APAC hydrogel base is losing relevance. If growth is concentrated in one side of the portfolio and the older base is being rationalized, the lagging segment belongs in Dogs because it is not the source of future expansion.

• Revenue decline signals weak demand, not temporary noise.
• Portfolio rationalization signals management is trimming the line, not expanding it.
• Softness in Japan and China shows the problem is regional, not isolated.
• Premium products are offsetting the weakness, which makes the legacy base less important.

Recall-impacted media inside CooperSurgical also fits Dogs. The company said the embryo culture media franchise remained weighed down by the December 2023 voluntary recall. In Q2 2026, it recorded a $324.1M litigation liability, partially offset by $52.5M of insurance recovery, for a net pre-tax charge of $271.6M. Management also said more than 95.0% of claims related to the recall had been settled by June 2026. Even with settlements advancing, the franchise still carries a legal shadow, no clear growth profile in the disclosed data, and a real cash and management burden. That is not a healthy market leader. It looks like a Dog because it consumes resources while offering limited strategic upside.

Legal drain on CooperSurgical is another Dog-like issue. The Q2 2026 GAAP net loss was $(78.1M), driven by the $271.6M litigation charge. The company also faces a tort product liability case filed in New Mexico in June 2025. Its FY 2026 free cash flow guidance of about $650M excludes litigation payouts, which means legal costs can still reduce cash available for debt reduction, acquisitions, or reinvestment. A business that produces cash but then loses flexibility to legal claims is not acting like a growth asset. It behaves like a Dog because the economics are being dragged down by non-operating risk.

Tariff and freight pressure adds another layer. The company said higher costs from tariffs and freight remained material drivers of gross margin pressure in June 2026. It estimated full-year 2026 tariff expense at $22M, even after possible refunds of up to $15M. Adverse foreign exchange was mostly offset by operational efficiencies, but that still means the company had to work just to hold the line. In a low-growth or declining product category, weak pricing power makes cost inflation more damaging. That is why this pressure reinforces Dog status: the business is spending effort to defend margins instead of expanding returns.

• Legal charges reduce reported earnings and can distort operating performance.
• Cash settlement risk matters because free cash flow is what funds growth and returns.
• Tariffs and freight costs hit margins harder when demand is weak.
• Offsetting costs through efficiencies is defensive, not a sign of strength.

For academic work, you can treat these Dog segments as examples of businesses that should be harvested, managed for cash, or gradually exited rather than expanded. The key strategic point is that the company's premium eye care franchises and core surgical platforms are carrying the growth profile, while these older or burdened units mainly create drag.